| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Dermatology [L. J., J-F. A., J-H. S., C. H.] and Division of Immunology and Allergy [J-F. A., C. H.], University Hospital Geneva, 1211 Genève 14, Switzerland, and the Department of Dermatology, University Hospital Mainz, Mainz, Germany [H. J.]
Dendritic cells (DCs) phagocytose apoptotic influenza-infected monocytes
and cross-present influenza antigen to CD8+ T cells,
generating a specific CTL response. We investigated whether apoptotic
melanoma cells, presented by this mechanism, can lead to CTL responses
to tumor-associated antigens and melanoma cells. Apoptotic
HLA-A2- MEL-397 melanoma cells were internalized by
HLA-A2+ immature monocyte-derived DCs but failed to
induce maturation of DCs. When exposed to interleukin 6, interleukin
1ß, tumor necrosis factor
, and prostaglandin
E2, DCs containing apoptotic MEL-397 cell material matured
normally [cross-presenting DCs (cp-DCs)]. Autologous CD8+
CTL lines generated with cp-DCs produced tumor necrosis factor when
stimulated with HLA-A2-binding immunodominant peptides from
MelanA/MART1 and MAGE-3 (expressed by MEL-397 cells) but not tyrosinase
(absent in MEL-397). T2 target cells loaded with the respective
peptides were lysed by these cell lines, although to a lesser extent
than by CTL lines generated in the presence of mature DCs and peptides
from melanoma-associated antigens. In contrast, lines generated with
cp-DCs lysed HLA-A2+ MEL-526 melanoma cells or allogenic
HLA-A2+ cp-DCs efficiently, whereas the CTL generated with
DCs and peptides had little lytic activity. Mature DCs containing
apoptotic tumor cells may thus represent an alternative approach for
the therapy of malignant tumors.
This article has been cited by other articles:
![]() |
M. R. Shurin, A. I. Potapovich, Y. Y. Tyurina, I. L. Tourkova, G. V. Shurin, and V. E. Kagan Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer Cancer Res., March 15, 2009; 69(6): 2487 - 2496. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Franki, K. K. Steward, D. J. Betting, K. Kafi, R. E. Yamada, and J. M. Timmerman Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo Blood, February 1, 2008; 111(3): 1504 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Johansson, L. Walther-Jallow, A. Smed-Sorensen, and A.-L. Spetz Triggering of Dendritic Cell Responses after Exposure to Activated, but Not Resting, Apoptotic PBMCs J. Immunol., August 1, 2007; 179(3): 1711 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Park, W. H. Choi, Y. B. Kim, C. S. Ha, H. Lee, Y.-D. Kwon, O.-M. Choi, Y.-J. Lee, and W. S. Koh Potential Side Effects of Dendritic Cells Pulsed with Allogenic Melanoma Cell Lysate in Mice International Journal of Toxicology, January 1, 2007; 26(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Batchu, A. M. Moreno, S. M. Szmania, G. Bennett, G. C. Spagnoli, S. Ponnazhagan, B. Barlogie, G. Tricot, and F. van Rhee Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma Cancer Res., November 1, 2005; 65(21): 10041 - 10049. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tanaka, S. Koido, M. Ohana, C. Liu, and J. Gong Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells J. Immunol., February 1, 2005; 174(3): 1274 - 1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Hoffmann, J. A. Kench, A. Vondracek, E. Kruk, D. L. Daleke, M. Jordan, P. Marrack, P. M. Henson, and V. A. Fadok Interaction between Phosphatidylserine and the Phosphatidylserine Receptor Inhibits Immune Responses In Vivo J. Immunol., February 1, 2005; 174(3): 1393 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Prasad, K. J. Farrand, S. A. Matthews, J. H. Chang, R. S. McHugh, and F. Ronchese Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells J. Immunol., January 1, 2005; 174(1): 90 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jalili, M. Makowski, T. Switaj, D. Nowis, G. M. Wilczynski, E. Wilczek, M. Chorazy-Massalska, A. Radzikowska, W. Maslinski, L. Bialy, et al. Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells Clin. Cancer Res., July 1, 2004; 10(13): 4498 - 4508. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ebstein, C. Sapede, P.-J. Royer, M. Marcq, C. Ligeza-Poisson, I. Barbieux, L. Cellerin, G. Dabouis, and M. Gregoire Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1322 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Atanackovic, N. K. Altorki, E. Stockert, B. Williamson, A. A. Jungbluth, E. Ritter, D. Santiago, C. A. Ferrara, M. Matsuo, A. Selvakumar, et al. Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients J. Immunol., March 1, 2004; 172(5): 3289 - 3296. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. S. Zimmermann, A. Bondanza, A. Monno, P. Rovere-Querini, A. Corti, and A. A. Manfredi TNF-{alpha} Coupled to Membrane of Apoptotic Cells Favors the Cross-Priming to Melanoma Antigens J. Immunol., February 15, 2004; 172(4): 2643 - 2650. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. van den Broeke, E. Daschbach, E. K. Thomas, G. Andringa, and J. A. Berzofsky Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity J. Immunol., December 1, 2003; 171(11): 5842 - 5852. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Crittenden, M. Gough, K. Harrington, K. Olivier, J. Thompson, and R. G. Vile Expression of Inflammatory Chemokines Combined with Local Tumor Destruction Enhances Tumor Regression and Long-term Immunity Cancer Res., September 1, 2003; 63(17): 5505 - 5512. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mehrotra, R. Stevens, R. Zengou, N. G. Chakraborty, L. H. Butterfield, J. S. Economou, D. I. Dorsky, and B. Mukherji Regulation of Melanoma Epitope-specific Cytolytic T Lymphocyte Response by Immature and Activated Dendritic Cells, in Vitro Cancer Res., September 1, 2003; 63(17): 5607 - 5614. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Messmer, B. Messmer, and N. Chiorazzi The global transcriptional maturation program and stimuli-specific gene expression profiles of human myeloid dendritic cells Int. Immunol., April 1, 2003; 15(4): 491 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Akiyama, S. Ebihara, A. Yada, K. Matsumura, S. Aiba, T. Nukiwa, and T. Takai Targeting Apoptotic Tumor Cells to Fc{gamma}R Provides Efficient and Versatile Vaccination Against Tumors by Dendritic Cells J. Immunol., February 15, 2003; 170(4): 1641 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yu, S. Kusmartsev, F. Cheng, M. Paolini, Y. Nefedova, E. Sotomayor, and D. Gabrilovich Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 285 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Miller, S. Lahrs, V. G. Pillarisetty, A. B. Shah, and R. P. DeMatteo Adenovirus Infection Enhances Dendritic Cell Immunostimulatory Properties and Induces Natural Killer and T-Cell-mediated Tumor Protection Cancer Res., September 15, 2002; 62(18): 5260 - 5266. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schnurr, C. Scholz, S. Rothenfusser, P. Galambos, M. Dauer, J. Robe, S. Endres, and A. Eigler Apoptotic Pancreatic Tumor Cells Are Superior to Cell Lysates in Promoting Cross-Priming of Cytotoxic T Cells and Activate NK and {gamma}{delta} T Cells Cancer Res., April 1, 2002; 62(8): 2347 - 2352. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Q. Zhao, X.-L. Huang, P. Gupta, L. Borowski, Z. Fan, S. C. Watkins, E. K. Thomas, and C. R. Rinaldo Jr. Induction of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ and CD4+ T-Cell Reactivity by Dendritic Cells Loaded with HIV-1 X4-Infected Apoptotic Cells J. Virol., February 22, 2002; 76(6): 3007 - 3014. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Dhodapkar, J. Krasovsky, B. Williamson, and M. V. Dhodapkar Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells J. Exp. Med., January 7, 2002; 195(1): 125 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Pietra, R. Mortarini, G. Parmiani, and A. Anichini Phases of Apoptosis of Melanoma Cells, but not of Normal Melanocytes, Differently Affect Maturation of Myeloid Dendritic Cells Cancer Res., November 1, 2001; 61(22): 8218 - 8226. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Salio, D. Shepherd, P. R. Dunbar, M. Palmowski, K. Murphy, L. Wu, and V. Cerundolo Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC J. Immunol., August 1, 2001; 167(3): 1188 - 1197. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Feng, Y. Zeng, L. Whitesell, and E. Katsanis Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity Blood, June 1, 2001; 97(11): 3505 - 3512. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |